D.A. Davidson & CO. Grows Stock Holdings in Abbott Laboratories $ABT

D.A. Davidson & CO. lifted its stake in Abbott Laboratories (NYSE:ABT) by 9.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 182,233 shares of the healthcare product maker’s stock after purchasing an additional 15,625 shares during the quarter. D.A. Davidson & CO.’s holdings in Abbott Laboratories were worth $22,832,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABT. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $27,000. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $31,000. Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $33,000. Finally, Copia Wealth Management purchased a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Performance

ABT opened at $91.16 on Monday. Abbott Laboratories has a 12-month low of $90.72 and a 12-month high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $158.76 billion, a PE ratio of 25.53, a P/E/G ratio of 1.52 and a beta of 0.79. The firm has a 50 day moving average of $105.96 and a two-hundred day moving average of $117.11.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period last year, the firm posted $1.09 EPS. Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 70.59%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Oppenheimer decreased their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Citigroup reduced their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Benchmark reduced their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Finally, Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research report on Wednesday, April 22nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $119.43.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.